CompletedPhase 3NCT01777152
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen Inc.
- Principal Investigator
- Thomas Manley, MDSeagen Inc.
- Intervention
- brentuximab vedotin(drug)
- Enrollment
- 452 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2020
Study locations (30)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- City of Hope National Medical Center, Duarte, California, United States
- Stanford Cancer Center, Stanford, California, United States
- Shands Cancer Center / University of Florida, Gainesville, Florida, United States
- Orlando Health, Inc., Orlando, Florida, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
- Holden Comprehensive Cancer Center / University of Iowa, Iowa City, Iowa, United States
- University of Kansas Cancer Center, Westwood, Kansas, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Millennium Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01777152 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06137144AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.AstraZeneca
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation